CureVac (NASDAQ:CVAC) Posts Quarterly Earnings Results

CureVac (NASDAQ:CVAC) released its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share for the quarter, Zacks reports. The business had revenue of $15.44 million during the quarter. CureVac had a return on equity of 21.98% and a net margin of 20.72%.

CureVac Trading Up 11.5 %

NASDAQ:CVAC opened at $3.19 on Friday. The stock has a market capitalization of $714.18 million, a price-to-earnings ratio of 5.80 and a beta of 2.48. CureVac has a 52 week low of $2.22 and a 52 week high of $5.28. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average of $3.13 and a 200 day moving average of $3.16.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price target on shares of CureVac in a research report on Friday, February 14th.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.